GlassScriptPhysician profile
Julia A Hemman
NPI 1831766807
$1,321.35
in general payments reported to CMS, 2019-2025
17 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $148 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $241.62 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $241.11 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $173.26 | 2024-2025 | |
| Amgen INC. | $129.40 | 2024-2025 | Evenity, Prolia, Prolia |
| Sumitomo Pharma America, INC. | $124.87 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $76.42 | 2024-2025 | Veozah |
| Abbvie INC. | $75.80 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.15 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $42.54 | 2025 | Trelegy Ellipta, Boostrix, Shingrix |
| Novo Nordisk INC | $31.89 | 2025 | Wegovy |
| Beta Bionics, INC. | $27.70 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Eisai INC. | $26.37 | 2025 | |
| Cranial Technologies, INC | $19.93 | 2025 | Doc Band |
| Novartis Pharmaceuticals Corporation | $19.16 | 2024 | |
| Lilly USA, LLC | $15.14 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $14.60 | 2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $12.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Hemman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.